One limitation of this research isthe use of synthetic PCA3 mimicDNA instead of actual PCA3-RNA from clinical prostate cancer patients.Although synthetic mimics are a convenient first proof-of-conceptto validate assay sensitivity and performance, patient-derived PCA3-RNAsamples must be utilized to thoroughly confirm clinical usefulness.Future research will be focused on evaluating the TR-FRET assay constructedwith clinically relevant samples, such as patients’ blood orurine, and conducting in vitro assays on cancer cell lines. Here, PCA3 is linked to prostate cancer.